France Hepatitis B Drugs Market Report 2022 to 2030

France Hepatitis B Drugs Market Analysis

$ 3999

France Hepatitis B Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The factors such as growth of pharmaceutical industry, increase in ageing population, upsurge in healthcare expenditure, urbanization leading to better monitoring and screening procedures and increase in liver cancer and cirrhosis deaths due to HBV would drive the growth of Hepatitis B drugs market. Some of the major key players in this market are Apotex Inc, Accord Healthcare, Arbutus Biopharma, Aurobindo Pharma, Arrowhead Pharmaceuticals, Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Gilead Sciences, Inc., Lupin Pharmaceuticals, Inc., etc.

ID: IN10FRPH298 CATEGORY: Pharmaceuticals GEOGRAPHY: France AUTHOR: Dr. Netal Patel

Buy Now

France Hepatitis B Drugs Market Analysis Summary

France Hepatitis B Drugs Market is valued at around $115 Mn in 2022 and is projected to reach $139.9 Mn by 2030, exhibiting a CAGR of 2.48% during the forecast period 2023-2030.

Hepatitis B is a potentially fatal liver infection brought on by the Hepatitis B Virus (HBV). It has a big impact on global health. It considerably raises the risk of cirrhosis and liver cancer-related death and can result in persistent infection. There is a secure and reliable vaccine against hepatitis B that provides 98 to 100 percent protection. The virus is most usually transferred from mother to kid during pregnancy, childbirth, and delivery, during sex with an infected partner, during injections, when coming into touch with blood or other bodily fluids, or when being cut by sharp instruments. Hepatitis B affects 296 Mn people worldwide, with 1.5 Mn new cases recorded each year, according to estimates from the WHO. An estimated 820 000 people died from hepatitis B in 2019, primarily from cirrhosis and hepatocellular carcinoma (primary liver cancer). Five oral medications and one injectable have FDA approval for the treatment of hepatitis B. The more modern oral medications are more potent, less likely to result in viral resistance, and have fewer side effects. The medication can help reduce the body's viral load and risk of repercussions even though it cannot cure the sickness. You may undergo routine blood tests to monitor the effectiveness of the medication and screen for drug resistance.

The factors such as growth of pharmaceutical industry, increase in ageing population, upsurge in healthcare expenditure, urbanization leading to better monitoring and screening procedures and increase in liver cancer and cirrhosis deaths due to HBV would drive the growth of Hepatitis B drugs market. The global Hepatitis B Drugs market’s major key players are Apotex Inc, Accord Healthcare, Arbutus Biopharma, Aurobindo Pharma, Arrowhead Pharmaceuticals, Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Gilead Sciences, Inc., Lupin Pharmaceuticals, Inc., Par Pharmaceutical, Merck Sharp and Dohme Corp.,Teva Pharmaceutical Industries Ltd. and Zydus Pharmaceuticals, Inc. The Vitec Group plc, FUJIFILM Wako Pure Chemical Corporation, Novartis AG, Teva Pharmaceutical Industries Ltd., LGM Pharma., Lannett, NorthStar Rx LLC, and Par Pharmaceutical.

Market Dynamics

Market Growth Drivers

Transmission of contagious diseases is a major cause of concern on a global scale. To stop the spread of these diseases, the United Nations has outlined the 2030 Agenda for Sustainable Development, which also lays out 17 goals for sustainable development that are focused on a number of challenging areas. Viral hepatitis poses a hazard to global public health, prompting governmental organisations like the World Health Organization (WHO) to focus on finding solutions that can help achieve the targets established for 2030. The WHO has developed a set of five strategic decisions to aid governments in increasing public awareness of communicable illnesses and to support drug producers globally. This will surely act as a driver for Hepatitis B drugs market.

Market Restraints

The absence of a suitable healthcare infrastructure in a number of nations where the incidence of viral infection is noticeably high is one of the major factors anticipated to limit the market's growth. The lengthy licencing process for novel therapies and the high cost of therapy in many developing nations are additional aspects that are anticipated to restrict the expansion of the global market for hepatitis B therapeutic drugs in the future years.

Competitive Landscape

Key Players

Gilead Sciences Inc.
GlaxoSmithKline plc
Bristol Myers Squibb
Johnson & Johnson
Merck & Co., Inc.
Novartis AG
AbbVie Inc.
Roche Holding AG
AstraZeneca plc
Pfizer Inc.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

France Hepatitis B Drugs Market Segmentation

By Disease Type

Acute
Chronic

By Drugs

telbivudine
entecavir
tenofovir disoproxil
lamivudine
others

By Distribution Channel

Hospital
Retail pharmacies
Online pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.